drbob66

Readers Ask: Antares, GenVec, Xoma,

Hilarious!

Thanks for the laugh.


On Sep 23 08:40 AM Timothy Sykes wrote:

> This guy MUST be a paid promoter or total sucker to say he likes
> GVBP, which has been proven to be a blatant fraud, as they were a
> travel agency last month, now they want to cure cancer with $35,000
> in the bank, they use recycled press releases from "NextGen Bio (NXGB),
> Genova's disclaimer on their own website mistakenly lists "Nextgen
> Bio" as the company name, not to mention spending millions hiring
> stock promoters! Careful SA, disclosure is good for people who own
> stock, but how much has VFC been paid to say this company is real?
>
>
> I am currently short this stock, yes, and making a bundle, but I
> make my $ trading, not through scummy compensation, see my research
> and learn:
>
> timothysykes.com/blog/..../

Extreme FDA Trades: 30 Stocks Under 5 Bucks

intranasal ketamine? really? Thanks for this info, this is interesting. I had no idea anyone was developing ketamine for this purpose.

For anyone interested, check out this link about DM Turner, a "psychonautic researcher" who drowned in his bathtub while tripping on "Special K." He was hooked on the stuff for many years.

www.erowid.org/culture...


On Aug 10 01:06 PM Mike Havrilla wrote:

> Check out this good, recent update article for JAV:
> seekingalpha.com/artic...
>
>
> JAV also mentioned above in my extreme trade article for pending
> Ereska Phase 3 results:
>
> Ereska is a non-opiate pain drug being developed by (1) Javelin Pharma
> (AMEX:seekingalpha.com/symbo...)($1.90) for the acute treatment
> of moderate to severe pain in military, trauma, post-operative, and
> emergency room settings with the potential for treating breakthrough
> pain from cancer as well. The drug is delivered by a disposable manual
> pump with a rapid onset and duration of pain relief of about two
> hours without opiate side effects such as respiratory depression.
> JAV expects to release the primary endpoint data from the Ereska
> (intranasal ketamine) Phase 3 pivotal trial in mid-2009, which consists
> of 220 adult patients to evaluate the safety and effectiveness of
> the drug in the treatment of acute pain (arising from surgery, trauma,
> or injury).